$GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Healthcare
Sector
Biotechnology
Industry
Thomas D. Zindrick
CEO
24
Employees
$2.55
Current Price
$106.54M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 3 | $146,669.69 | 54,403 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 6 | $159,421.38 | 58,732 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 7 | $194,319.78 | 70,732 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Cappello Joseph Chief Technical Officer | Sale | 10,257 | $2.74 | $28,112.39 | View Details |
| Aug 31, 2026 | Zindrick Thomas President and CEO | Sale | 34,463 | $2.67 | $91,899.04 | View Details |
| Aug 31, 2026 | Yu Yong Chief Scientific Officer | Sale | 9,683 | $2.75 | $26,658.27 | View Details |
| Aug 4, 2026 | Yu Yong Chief Scientific Officer | Sale | 653 | $2.94 | $1,922.04 | View Details |
| Aug 4, 2026 | Cappello Joseph Chief Technical Officer | Sale | 653 | $2.95 | $1,924.20 | View Details |
| Aug 4, 2026 | Zindrick Thomas President and CEO | Sale | 3,023 | $2.95 | $8,905.46 | View Details |
| Jul 1, 2026 | Smither John W Director | Sale | 12,000 | $2.91 | $34,898.40 | View Details |
18 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.